<p class="frontmatter-fieldnotes disclaimernew" style="margin-bottom:15px;">This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s <a href="/pages/termsofuse.aspx" target="_blank">Terms & Conditions</a>.</p> <div><img id="cr_header_img" alt="Case Report Header" src="/PublishingImages/2011_case_report.gif" width="600px" height="40px">
<script>aheadofprint='feature';</script>
<div id="_idContainer000">
<p class="title-left"><span class="bold">A Case of Autoimmune Encephalitis in a Patient With Alcohol Use Disorder</span></p>
<p class="byline-regular">Cristian L. Valquier, BS,<span class="superscript">a</span> and Alëna A. Balasanova, MD<span class="superscript">b,</span><span class="asterisk">*</span></p>
<p class="drop-cap-with-body-text"><span class="bold-14pt-for-cap"><span class="bold">W</span></span>e present a case of a patient with alcohol use disorder (AUD) and new-onset mental status changes due to anti–<span class="italic">N</span>-methyl-<span class="smallcaps">d</span>-aspartate (NMDA) receptor (anti-NMDAR) encephalitis. AUD was a confounding factor, and accurate diagnosis and treatment were found at the crossroads of addiction psychiatry and neurology. The patient returned to baseline cognition after 5 days of intravenous immunoglobulin (IVIG).</p>
<p class="subheads-subhead-2">Description of Case</p>
<p class="body-text">A 37-year-old Black woman was brought to the hospital after her partner found her at home, awake and seemingly alert but nonverbal except for bursts of profanity. He noted that onset of these behaviors had followed an episode of drinking. The patient took no medications and had no significant medical problems apart from AUD (per <span class="italic">DSM-5</span> criteria). She was admitted to the general hospital service with amnesia, lethargy, psychomotor retardation, and flattened affect. Consults were ordered for addiction psychiatry and neurology, and the patient received an extensive neurologic workup including imaging and laboratory studies. Findings of urine drug screen (UDS) and blood alcohol level (BAL) testing were negative. Imaging was unremarkable, and electroencephalogram showed nonspecific theta slowing. A list of pertinent diagnostic study findings is reported in <span class="callout"><a href="#" onclick="createFigure('T1'); return false;" title="">Table 1</a></span>.</p>

<div id="figure-2"> <a href="#" onclick="createFigure('T1'); return false;"><img src="20l02606T1.gif" alt="Table 1" id="T1" border="0" /></a>
      <p class="click-to-enlarge">Click figure to enlarge</p>
    </div>

<p class="body-text">Symptom-triggered benzodiazepine treatment was initiated for suspected alcohol withdrawal. The patient showed no autonomic signs of alcohol withdrawal and became increasingly confused while receiving benzodiazepines, leading to their being discontinued on hospital day 9. Despite thiamine levels within normal limits, the patient received parenteral supplementation for the duration of her hospital stay, along with daily multivitamin and folic acid.</p>
<p class="body-text">Addiction psychiatry specialists believed the patient’s presentation was not consistent with alcohol withdrawal. Her unexplained fluctuating mentation in the setting of primarily unremarkable laboratory and imaging findings thus led to considering cerebrospinal fluid (CSF) studies. The CSF encephalitis panel included NMDAR antibodies, oligoclonal bands, and other markers seen in a variety of neurologic diseases. The patient’s results returned shortly prior to discharge and showed oligoclonal bands in the serum and the CSF and anti-NMDAR antibodies (NMDAR IgG) in the serum but not the CSF.</p>
<p class="body-text">On hospital day 20, the patient’s mentation spontaneously recovered to its baseline level. She was discharged in stable condition without a clear etiology for her presenting symptoms. Wernicke encephalopathy was considered earlier in the hospitalization, but was later deemed unlikely given the spontaneous remission of altered mentation and thiamine levels within normal limits. The official diagnoses at the time of discharge were altered mentation, AUD, and vitamin deficiencies (vitamins B<span class="subscript">3</span>, B<span class="subscript">6</span>, and D).</p>
<p class="body-text">One month later, the patient’s sister found her disrobed in her neighborhood in the snowy winter weather. The patient was incoherent and non-redirectable; her sister brought her to the hospital with concerns about recent alcohol use. Onset was preceded by 1 week of irritability, fatigue, decreased appetite, and auditory and visual hallucinations. Notable findings on the second admission were a reduction in body mass index from 26.37 to 19.03 kg/m<span class="superscript">2</span>, persecutory and grandiose delusions, ideas of reference, agitation, and social disinhibition. Findings of BAL testing and UDS were again negative, although collateral information from family suggested recent alcohol use. Over several days, the patient grew progressively more agitated, requiring a bedside sitter to prevent elopement. Benzodiazepines were used as needed for recurrent episodes of acute agitation and disorientation for the first 7 days of the hospitalization with minimal improvement of mental status. Addiction psychiatry specialists were consulted to help with management of agitation and psychosis; benzodiazepines were discontinued, and olanzapine 10 mg was initiated at bedtime with an additional 5 mg of olanzapine as needed for agitation on hospital days 8–13, resulting in significant reduction in agitation and psychotic symptoms.</p>
<p class="body-text">Neurology workup from the first admission was reviewed and partially repeated due to unusual findings of negative CSF markers in the setting of positive serum markers. (<span class="callout"><a href="#" onclick="createFigure('T1'); return false;" title="">Table 1</a></span>). This time, NMDAR IgG was positive in the CSF and the serum. Malignancy screen using positron emission tomography scan was unrevealing. A 5-day course of IVIG treatment was initiated, and the patient’s mentation improved dramatically, returning to its baseline level by day 5. Olanzapine was discontinued on the last day of IVIG treatment.</p>
<p class="body-text">The patient expressed a desire for sobriety from alcohol but an unwillingness to pursue formal treatment. She was amenable to a trial of naltrexone 50 mg daily and committed to following up with her primary care physician for ongoing management. Outpatient neurology follow-up was also scheduled. The patient was discharged without the need for antipsychotics or ongoing psychiatric care.</p>
<p class="subheads-subhead-2">Discussion</p>
<p class="body-text">Patients that present to the health care system with predominantly psychiatric symptoms can have an underlying medical disease. Determining whether symptoms are from a primary psychiatric disorder or secondary to another medical condition can pose a diagnostic dilemma. Psychiatric diagnostic criteria are rarely pathognomonic and often overlap with symptoms of medical illness.<span class="htm-cite"><a href="#ref1">1</a></span> When features of an illness are atypical of any suspected psychiatric disease, alternative medical etiologies should be considered.<span class="htm-cite"><a href="#ref2">2</a></span> Although substance use disorder has significant comorbidity with psychotic disorders,<span class="htm-cite"><a href="#ref3">3</a></span> primary psychiatric and addiction etiology are diagnoses of exclusion, particularly if the alternative diagnosis is a potentially treatable autoimmune disease.<span class="htm-cite"><a href="#ref4">4</a></span></p>
<p class="body-text">A conclusive diagnosis of anti-NMDAR encephalitis requires positive NMDAR IgG in both the serum and the CSF.<span class="htm-cite"><a href="#ref5">5</a>,<a href="#ref6">6</a></span> It is atypical for anti-NMDAR encephalitis to present with positive serum but not matching positive CSF NMDAR IgG,<span class="htm-cite"><a href="#ref5">5</a>,<a href="#ref6">6</a></span> as was the case in our patient’s first hospitalization, although matching positive oligobands are found in only about 60% of cases.<span class="htm-cite"><a href="#ref7">7</a></span> Because onset of symptoms and positive laboratory markers may not strictly coincide, careful consideration of all potential causes is critical.</p>
<p class="body-text">In times of diagnostic uncertainty, attributing seemingly unexplained symptoms to a patient’s history of substance use disorder, such as Wernicke encephalopathy, may seem appealing. In our patient’s case, thiamine levels within normal limits and spontaneous resolution of symptoms during the first hospitalization, in conjunction with positive NMDAR IgG in both the serum and CSF on the second admission, ruled out this diagnosis.</p>
<p class="subheads-subhead-2">Conclusion</p>
<p class="body-text">In this case report, we present the onset and course of anti-NMDAR encephalitis in a patient with alcohol use disorder. Determining the diagnosis was complicated by suspected alcohol withdrawal, and evaluation by addiction psychiatry specialists helped prompt workup for other medical etiologies. Our patient returned to baseline cognition after a course of IVIG and was discharged without the need for psychotropic medications.</p>
<p class="end-matter"><span class="bold-italic">Published online:</span> December 10, 2020.</p>
<p class="end-matter"><span class="bold-italic">Potential conflicts of interest:</span> <span class="semibold">Dr Balasanova</span> and <span class="semibold">Mr Valquier</span> report no conflicts of interest.</p>
<p class="end-matter"><span class="bold-italic">Funding/support:</span> There were no sources of financial or material support. There were no sources of external funding.</p>
<p class="end-matter"><span class="bold-italic">Patient consent:</span> The patient has provided permission to publish these features of her case, and the identity of the patient has been protected.</p>
<p class="references_references-heading"><span class="bold">REFERENCES</span></p>
<p class="references-references-text-1-9"><a name="ref1"></a><span class="htm-ref"> 1. </span>McKee J, Brahm N. Medical mimics: differential diagnostic considerations for psychiatric symptoms. <span class="italic">Ment Health Clin</span>. 2016;6(6):289–296. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=29955484&dopt=Abstract" target="_blank"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.9740/mhc.2016.11.289" target="_blank"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-1-9"><a name="ref2"></a><span class="htm-ref"> 2.</span> Freudenreich O. Differential diagnosis of psychotic symptoms: medical mimics. <span class="italic">Psychiatr Times</span>. 2010;27(12):56–61.</p>
<p class="references-references-text-1-9"><a name="ref3"></a><span class="htm-ref"> 3. </span>Caton CLM, Drake RE, Hasin DS, et al. Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. <span class="italic">Arch Gen Psychiatry</span>. 2005;62(2):137–145. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15699290&dopt=Abstract" target="_blank"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1001/archpsyc.62.2.137" target="_blank"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-1-9"><a name="ref4"></a><span class="htm-ref"> 4. </span>Davies G, Irani SR, Coltart C, et al. Anti-<span class="italic">N</span>-methyl-<span class="smallcaps">d</span>-aspartate receptor antibodies: a potentially treatable cause of encephalitis in the intensive care unit. <span class="italic">Crit Care Med</span>. 2010;38(2):679–682. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20016378&dopt=Abstract" target="_blank"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1097/CCM.0b013e3181cb0968" target="_blank"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-1-9"><a name="ref5"></a><span class="htm-ref"> 5. </span>Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. <span class="italic">Lancet Neurol</span>. 2016;15(4):391–404. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26906964&dopt=Abstract" target="_blank"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1016/S1474-4422(15)00401-9" target="_blank"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-1-9"><a name="ref6"></a><span class="htm-ref"> 6. </span>Kayser MS, Dalmau J. Anti-NMDA receptor encephalitis in psychiatry. <span class="italic">Curr Psychiatry Rev</span>. 2011;7(3):189–193. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24729779&dopt=Abstract" target="_blank"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.2174/157340011797183184" target="_blank"><span class="pubmed-crossref">CrossRef</span></a></p>
<p class="references-references-text-1-9"><a name="ref7"></a><span class="htm-ref"> 7. </span>Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. <span class="italic">Lancet Neurol</span>. 2011;10(1):63–74. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21163445&dopt=Abstract" target="_blank"><span class="pubmed-crossref">PubMed</span></a> <a href="https://doi.org/10.1016/S1474-4422(10)70253-2" target="_blank"><span class="pubmed-crossref">CrossRef</span></a></p><div id="pcccrend">
<p class="front-matter-rule"><span class="superscript">a</span>College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska</p>
<p class="front-matter"><span class="superscript">b</span>Department of Psychiatry, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska</p>
<p class="front-matter"><span class="asterisk">*</span><span class="italic">Corresponding author:</span> Alëna A. Balasanova, MD, Department of Psychiatry, Poynter Hall 5th Floor, University of Nebraska Medical Center, 985578 Nebraska Medical Center, Omaha, NE 68198-5578 <span class="hyperlink">(<a href="mailto:alena.balasanova@unmc.edu">alena.balasanova@unmc.edu</a>)</span>.</p>
<p class="front-matter"><span class="italic">Prim Care Companion CNS Disord 2020;22(6):20l02606</span></p>
<p class="front-matter-rule"><span class="bold-italic">To cite:</span> Valquier CL, Balasanova AA. A case of autoimmune encephalitis in a patient with alcohol use disorder. <span class="italic">Prim Care Companion CNS Disord</span>. 2020;22(6):20l02606.</p>
<p class="doi-line"><span class="bold-italic">To share:</span> https://doi.org/<span class="doi">10.4088/PCC.20l02606</span></p>
<p class="front-matter"><span class="italic">© Copyright 2020 Physicians Postgraduate Press, Inc.</span></p></div>
</div>
</div>